- Glenview Capital Management’s 13F portfolio value decreased from ~$5.17B to ~$3.96B this quarter.
- They increased Alight (ALIT), Dun & Bradstreet (DNB), and United Health Svcs. (UHS) while reducing Cigna (CI), Corteva (CTVA), and McKesson (MCK).
- The top three individual stock stakes are CVS Health (CVS), Global Payments (GPN), and Tenet Healthcare (THC). They add up to ~34% of the portfolio.
This article is part of a series that provides an ongoing
analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly
basis. It is based on Robbins’ regulatory 13F Form filed on 2/14/2025. Please
visit our Tracking
Larry Robbins’ Glenview Capital Management Portfolio article for an idea on
his investment philosophy and our previous
update for the fund’s moves during Q3 2024.
This quarter, Robbins’ 13F portfolio value decreased from
~$5.17B to ~$3.96B. There are 23 positions that are significantly large. The
spreadsheet below lists those larger positions individually. The top five
individual stock stakes are CVS Health (CVS), Global Payments (GPN), Tenet
Healthcare (THC), Alight (ALIT), and Teva Pharma (TEVA). Together they are at
~44% of the 13F assets.
To learn about individual investing, check out the classics The Intelligent Investor and Security Analysis.
The spreadsheet below highlights changes to Robbins’ 13F
stock holdings in Q4 2024:
Source: John Vincent. Data constructed from Glenview Capital
Management’s 13F filings for Q3 2024 and Q4 2024.
No comments :
Post a Comment